AUPH Aurinia Pharmaceuticals, Inc.

19.26-1.11 (-5.45%)
Close: February 24, 2020

19.10-0.16 (-0.83%)
After hours

Quote

Previous Close
$19.26
Day Range
$19.00-$19.82
52 Week Range
$3.52-$21.93
Volume
2,011,317
Avg Volume
1,511,339
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$2.06B
Enterprise Value (EV)
$1.94B
PE Ratio
-
EV/EBITDA
-35.48
Price/Sales
-
Price/Book
18.32
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$54.59M
EPS, ttm
-$0.69
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
-
Debt to Equity
-
Debt
$NAN
Cash
$125.86M
Net Debt
-

Performance

Beta
0.77
200 Day Moving Avg
$9.49
50 Day Moving Avg
$19.58
52 Week Change
182.92%
YTD Change
-10.85%
1 Month Change
-0.10%
3 Month Change
209.15%
6 Month Change
226.44%
1 Year Change
214.71%
2 Year Change
252.75%
5 Year Change
429.12%

Share Count

Shares Outstanding
107.1M
Float
81.6M
Restricted Shares
25.5M
Restricted Shares, %
23.80%

Aurinia Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Peter S. Greenleaf

Website: http://www.auriniapharma.com

Description: Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Employees: 39